MedTrace Logo

A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF)

NCT01203943 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2019-11-19

No results posted yet for this study

Summary

The primary purpose of the study is to evaluate the safety and PK profile of CC-930 in idiopathic pulmonary fibrosis patients.

Conditions

Interventions

DRUG

CC-930

CC-930 50 mg PO daily up to 56 weeks beginning on Day 1

OTHER

Placebo

Placebo

DRUG

CC-930

CC-930 100 mg PO daily up to 56 weeks beginning on Day 1

DRUG

CC-930

C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • William Smith, MD · Celgene Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-01
Primary Completion
2012-01-31
Completion
2012-08-24

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01203943 on ClinicalTrials.gov